Synthetic Biologics Inc.'s CEO Jeff Riley talks about why the biopharma industry is interested now in the greater use of microbiome-focused techniques within drug R&D. He also highlights challenges within this research space and what to look out for from Synthetic Biologics in 2018.
Synthetic Biologics, a clinical company based in the US, has two drug candidates in development – ribaxamase and SYN-010 – that address Clostridium difficile infection (CDI) and irritable bowel syndrome with constipation (IBS-C)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?